• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

了解、评估和治疗细菌性败血症中的免疫、内皮和止血功能障碍。

Understanding, assessing and treating immune, endothelial and haemostasis dysfunctions in bacterial sepsis.

机构信息

Anaesthesiology and Intensive Care Department, University Hospital of Modena, University of Modena, Reggio Emilia, Italy.

Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland.

出版信息

Intensive Care Med. 2024 Oct;50(10):1580-1592. doi: 10.1007/s00134-024-07586-2. Epub 2024 Sep 2.

DOI:10.1007/s00134-024-07586-2
PMID:39222142
Abstract

The interplay between the immune system, coagulation, and endothelium is critical in regulating the host response to infection. However, in sepsis and other critical illnesses, a dysregulated immune response can lead to excessive alterations in these mechanisms, resulting in coagulopathy, endothelial dysfunction, and multi-organ dysfunction. This review aims to provide a comprehensive analysis of the pathophysiological mechanisms that govern the complex interplay between immune dysfunction, endothelial dysfunction, and coagulation in sepsis. It emphasises clinical significance, evaluation methods, and potential therapeutic interventions. Understanding these mechanisms is essential for developing effective treatments that can modulate the immune response, mitigate thrombosis, restore endothelial function, and ultimately improve patient survival.

摘要

免疫系统、凝血和内皮之间的相互作用对于调节宿主对感染的反应至关重要。然而,在脓毒症和其他危重病中,失调的免疫反应会导致这些机制的过度改变,从而导致凝血功能障碍、内皮功能障碍和多器官功能障碍。本综述旨在对脓毒症中免疫功能障碍、内皮功能障碍和凝血之间复杂相互作用的病理生理机制进行全面分析。它强调了临床意义、评估方法和潜在的治疗干预措施。了解这些机制对于开发有效的治疗方法至关重要,这些方法可以调节免疫反应、减轻血栓形成、恢复内皮功能,最终提高患者的生存率。

相似文献

1
Understanding, assessing and treating immune, endothelial and haemostasis dysfunctions in bacterial sepsis.了解、评估和治疗细菌性败血症中的免疫、内皮和止血功能障碍。
Intensive Care Med. 2024 Oct;50(10):1580-1592. doi: 10.1007/s00134-024-07586-2. Epub 2024 Sep 2.
2
Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome.炎症、凝血病与多器官功能障碍综合征的发病机制
Crit Care Med. 2001 Jul;29(7 Suppl):S99-106. doi: 10.1097/00003246-200107001-00032.
3
Bench-to-bedside review: endothelial cell dysfunction in severe sepsis: a role in organ dysfunction?从实验台到病床旁的综述:严重脓毒症中的内皮细胞功能障碍:在器官功能障碍中起作用吗?
Crit Care. 2003 Apr;7(2):130-8. doi: 10.1186/cc1864. Epub 2003 Jan 6.
4
Mechanisms and treatment of organ failure in sepsis.脓毒症器官衰竭的机制与治疗。
Nat Rev Nephrol. 2018 Jul;14(7):417-427. doi: 10.1038/s41581-018-0005-7.
5
Blood coagulation disorders in septic patients.脓毒症患者的凝血功能障碍
Wien Med Wochenschr. 2010 Mar;160(5-6):129-38. doi: 10.1007/s10354-009-0738-9.
6
The coagulopathy of sepsis: pathophysiology and management.脓毒症的凝血病:病理生理学与管理
Isr Med Assoc J. 2003 Jul;5(7):516-20.
7
Unraveling the Intricate Web: Complement Activation Shapes the Pathogenesis of Sepsis-Induced Coagulopathy.解开复杂的谜团:补体激活塑造了脓毒症诱导的凝血障碍的发病机制。
J Innate Immun. 2024;16(1):337-353. doi: 10.1159/000539502. Epub 2024 May 31.
8
Endothelial dysfunction: Pathophysiology and therapeutic targets for sepsis-induced multiple organ dysfunction syndrome.内皮功能障碍:脓毒症诱导的多器官功能障碍综合征的病理生理学和治疗靶点。
Biomed Pharmacother. 2024 Sep;178:117180. doi: 10.1016/j.biopha.2024.117180. Epub 2024 Jul 27.
9
The coagulopathy of acute sepsis.急性脓毒症的凝血病
Curr Opin Anaesthesiol. 2015 Apr;28(2):227-36. doi: 10.1097/ACO.0000000000000163.
10
Sepsis and multiple organ failure.脓毒症与多器官功能衰竭。
Contrib Nephrol. 2007;156:47-63. doi: 10.1159/000102070.

引用本文的文献

1
Association between endothelial activation and stress index and all-cause mortality risk in sepsis patients: a retrospective cohort analysis utilizing the MIMIC-IV database.脓毒症患者内皮激活与应激指数和全因死亡风险之间的关联:一项利用MIMIC-IV数据库的回顾性队列分析
BMC Infect Dis. 2025 Jul 31;25(1):966. doi: 10.1186/s12879-025-11363-x.
2
Prognostic value of albumin-corrected anion gap in critically ill patients with sepsis-associated liver injury: a retrospective study.白蛋白校正阴离子间隙在脓毒症相关肝损伤重症患者中的预后价值:一项回顾性研究
BMC Infect Dis. 2025 Jul 19;25(1):928. doi: 10.1186/s12879-025-11321-7.
3

本文引用的文献

1
Role of Angiopoietin/Tie2 System in Sepsis: A Potential Therapeutic Target.血管生成素/Tie2 系统在脓毒症中的作用:一个潜在的治疗靶点。
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241238010. doi: 10.1177/10760296241238010.
2
Persistent high sepsis-induced coagulopathy and sequential organ failure assessment scores can predict the 28-day mortality of patients with sepsis: A prospective study.持续的高脓毒症诱导性凝血障碍和序贯性器官衰竭评估评分可预测脓毒症患者的 28 天死亡率:一项前瞻性研究。
BMC Infect Dis. 2024 Mar 4;24(1):282. doi: 10.1186/s12879-024-09154-x.
3
Angiotensin ii therapy in refractory septic shock: which patient can benefit most? A narrative review.
Liquid‒liquid phase separation: a potentially fundamental mechanism of sepsis.
液-液相分离:脓毒症潜在的基本机制
Cell Death Discov. 2025 Jul 7;11(1):310. doi: 10.1038/s41420-025-02599-2.
4
Sivelestat-Loaded Neutrophil-Membrane-Coated Antioxidative Nanoparticles for Targeted Endothelial Protection in Sepsis.载有西维来司他的中性粒细胞膜包被抗氧化纳米颗粒用于脓毒症中靶向性内皮保护
Pharmaceutics. 2025 Jun 10;17(6):766. doi: 10.3390/pharmaceutics17060766.
5
Eno1 in sepsis-induced coagulopathy: a pleiotropic mechanism hypothesis involving immunomodulation and endothelial dysfunction.烯醇化酶1在脓毒症诱导的凝血病中的作用:一种涉及免疫调节和内皮功能障碍的多效性机制假说
Thromb J. 2025 Jun 12;23(1):62. doi: 10.1186/s12959-025-00750-8.
6
Clinical management of sepsis-associated acute respiratory distress syndrome: current evidence and future directions.脓毒症相关急性呼吸窘迫综合征的临床管理:当前证据与未来方向
Front Med (Lausanne). 2025 May 26;12:1531275. doi: 10.3389/fmed.2025.1531275. eCollection 2025.
7
Hemoadsorption in septic shock - CON.脓毒性休克中的血液吸附——对照
Intensive Care Med. 2025 May;51(5):948-950. doi: 10.1007/s00134-025-07911-3. Epub 2025 May 6.
8
[Specialty-specific knowledge as prerequisite for effective treatment of critically ill patients].[专业特定知识是有效治疗重症患者的先决条件]
Chirurgie (Heidelb). 2025 Jun;96(6):504-513. doi: 10.1007/s00104-025-02286-z. Epub 2025 Apr 25.
9
Protein C in adult patients with sepsis: from pathophysiology to monitoring and supplementation.成年脓毒症患者的蛋白C:从病理生理学到监测与补充
J Anesth Analg Crit Care. 2025 Apr 14;5(1):21. doi: 10.1186/s44158-025-00243-0.
10
Relationship between coagulopathy score and survival in critically ill patients with liver cirrhosis and sepsis: a retrospective study.肝硬化合并脓毒症重症患者凝血功能障碍评分与生存的关系:一项回顾性研究
BMC Infect Dis. 2025 Mar 26;25(1):418. doi: 10.1186/s12879-025-10848-z.
难治性感染性休克中的血管紧张素 II 治疗:哪些患者获益最大?一篇叙述性综述。
J Anesth Analg Crit Care. 2024 Feb 21;4(1):13. doi: 10.1186/s44158-024-00150-w.
4
2024 Focused Update: Guidelines on Use of Corticosteroids in Sepsis, Acute Respiratory Distress Syndrome, and Community-Acquired Pneumonia.2024聚焦更新:脓毒症、急性呼吸窘迫综合征及社区获得性肺炎中糖皮质激素使用指南
Crit Care Med. 2024 May 1;52(5):e219-e233. doi: 10.1097/CCM.0000000000006172. Epub 2024 Jan 19.
5
Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine.剖析脓毒症中失调的免疫反应:克服挑战,实现精准医学目标。
Lancet Respir Med. 2024 Apr;12(4):305-322. doi: 10.1016/S2213-2600(23)00330-2. Epub 2023 Dec 21.
6
Capillary leak and endothelial permeability in critically ill patients: a current overview.危重症患者的毛细血管渗漏与内皮通透性:当前概述
Intensive Care Med Exp. 2023 Dec 20;11(1):96. doi: 10.1186/s40635-023-00582-8.
7
Disseminated intravascular coagulation is strongly associated with severe acute kidney injury in patients with septic shock.弥散性血管内凝血与脓毒性休克患者的严重急性肾损伤密切相关。
Ann Intensive Care. 2023 Dec 1;13(1):119. doi: 10.1186/s13613-023-01216-8.
8
Prognostic Accuracy of the Different Scoring Systems for Assessing Coagulopathy in Sepsis: A Retrospective Study.不同评分系统评估脓毒症凝血障碍的预后准确性:一项回顾性研究。
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231207630. doi: 10.1177/10760296231207630.
9
Thromboinflammation in acute injury: infections, heatstroke, and trauma.急性损伤中的血栓炎症:感染、中暑与创伤。
J Thromb Haemost. 2024 Jan;22(1):7-22. doi: 10.1016/j.jtha.2023.07.020. Epub 2023 Aug 3.
10
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.前瞻性评估 TREM-1 抑制剂 nangibotide 在脓毒性休克患者中的疗效、安全性和最佳生物标志物富集策略(ASTONISH):一项双盲、随机、对照、2b 期试验。
Lancet Respir Med. 2023 Oct;11(10):894-904. doi: 10.1016/S2213-2600(23)00158-3. Epub 2023 May 31.